Cellular and Humoral Response After MRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients

Overview

Journal Am J Transplant

Publisher Elsevier

Specialty General Surgery

Date 2021 May 26

PMID 34036720

Citations 145

Authors

David Cucchiari

Natalia Egri

Marta Bodro

Sabina Herrera

Jimena Del Risco-Zevallos

Joaquim Casals-Urquiza

Frederic Cofan

Asuncion Moreno

Jordi Rovira

Elisenda Banon-Maneus

Maria J Ramirez-Bajo

Pedro Ventura-Aguiar

Anna Perez-Olmos

Marta Garcia-Pascual

Mariona Pascal

Anna Vilella

Antoni Trilla

Jose Rios

Eduard Palou

Manel Juan

Beatriu Bayes

Fritz Diekmann

Affiliations

Soon will be listed here.

Abstract

According to preliminary data, seroconversion after mRNA SARS-CoV-2 vaccination might be unsatisfactory in Kidney Transplant Recipients (KTRs). However, it is unknown if seronegative patients develop at least a cellular response that could offer a certain grade of protection against SARS-CoV-2. To answer this question, we prospectively studied 148 recipients of either kidney (133) or kidney-pancreas (15) grafts with assessment of IgM/IgG spike (S) antibodies and ELISpot against the nucleocapside (N) and the S protein at baseline and 2 weeks after receiving the second dose of the mRNA-1273 (Moderna) vaccine. At baseline, 31 patients (20.9%) had either IgM/IgG or ELISpot positivity and were considered to be SARS-CoV-2-pre-immunized, while 117 (79.1%) patients had no signs of either cellular or humoral response and were considered SARS-CoV-2-naïve. After vaccination, naïve patients who developed either humoral or cellular response were finally 65.0%, of which 29.9% developed either IgG or IgM and 35.0% S-ELISpot positivity. Factors associated with vaccine unresponsiveness were diabetes and treatment with antithymocytes globulins during the last year. Side effects were consistent with that of the pivotal trial and no DSAs developed after vaccination. In conclusion, mRNA-1273 SARS-CoV-2 vaccine elicits either cellular or humoral response in almost two thirds of KTRs.

Citing Articles

Vaccination for solid organ transplanted patients: Recommendations, efficacy, and safety.

Velikova T, Gerasoudis S, Batselova H World J Transplant. 2024; 14(4):92172.

PMID: 39697451 PMC: 11438943. DOI: 10.5500/wjt.v14.i4.92172.

Discovery of a pan anti-SARS-CoV-2 monoclonal antibody with highly efficient infected cell killing capacity for novel immunotherapeutic approaches.

Abba Moussa D, Vazquez M, Chable-Bessia C, Roux-Portalez V, Tamagnini E, Pedotti M Emerg Microbes Infect. 2024; 14(1):2432345.

PMID: 39584380 PMC: 11632933. DOI: 10.1080/22221751.2024.2432345.

Role of SARS-CoV-2-specific memory B cells promoting immune protection after booster vaccination in solid organ transplantation.

Donadeu L, Gomez-Olles S, Casanova F, Torija A, Lopez-Meseguer M, Boada-Perez M Front Immunol. 2024; 15:1463769.

PMID: 39439787 PMC: 11493670. DOI: 10.3389/fimmu.2024.1463769.

Human RP105 monoclonal antibody enhances antigen-specific antibody production in unique culture conditions.

Yamazaki T, Iwasaki K, Tomono S, Imai M, Miwa Y, Shizuku M iScience. 2024; 27(9):110649.

PMID: 39246445 PMC: 11380396. DOI: 10.1016/j.isci.2024.110649.

Immune response analysis of solid organ transplantation recipients inoculated with inactivated COVID-19 vaccine: A retrospective analysis.

Li J, Cao P, Chen Z, Deng R, Nie Y, Pang F Open Med (Wars). 2024; 19(1):20240980.

PMID: 38911255 PMC: 11193357. DOI: 10.1515/med-2024-0980.

References

Birdwell K, Ikizler M, Sannella E, Wang L, Byrne D, Ikizler T . Decreased antibody response to influenza vaccination in kidney transplant recipients: a prospective cohort study. Am J Kidney Dis. 2009; 54(1):112-21. PMC: 3772511. DOI: 10.1053/j.ajkd.2008.09.023. View

Jackson L, Anderson E, Rouphael N, Roberts P, Makhene M, Coler R . An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020; 383(20):1920-1931. PMC: 7377258. DOI: 10.1056/NEJMoa2022483. View

Manuel O, Pascual M, Hoschler K, Giulieri S, Alves D, Ellefsen K . Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. Clin Infect Dis. 2011; 52(2):248-56. DOI: 10.1093/cid/ciq104. View

Healy C, Rench M, Baker C . Implementation of cocooning against pertussis in a high-risk population. Clin Infect Dis. 2011; 52(2):157-62. DOI: 10.1093/cid/ciq001. View

Baden L, El Sahly H, Essink B, Kotloff K, Frey S, Novak R . Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020; 384(5):403-416. PMC: 7787219. DOI: 10.1056/NEJMoa2035389. View

Grupper A, Sharon N, Finn T, Cohen R, Israel M, Agbaria A . Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis. Clin J Am Soc Nephrol. 2021; 16(7):1037-1042. PMC: 8425628. DOI: 10.2215/CJN.03500321. View

Babel N, Anft M, Blazquez-Navarro A, Doevelaar A, Seibert F, Bauer F . Immune monitoring facilitates the clinical decision in multifocal COVID-19 of a pancreas-kidney transplant patient. Am J Transplant. 2020; 20(11):3210-3215. PMC: 7436473. DOI: 10.1111/ajt.16252. View

Grupper A, Rabinowich L, Schwartz D, Schwartz I, Ben-Yehoyada M, Shashar M . Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. Am J Transplant. 2021; 21(8):2719-2726. PMC: 8250589. DOI: 10.1111/ajt.16615. View

Boyarsky B, Werbel W, Avery R, Tobian A, Massie A, Segev D . Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients. JAMA. 2021; 325(17):1784-1786. PMC: 7961463. DOI: 10.1001/jama.2021.4385. View

10.

Boyarsky B, Werbel W, Avery R, Tobian A, Massie A, Segev D . Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. JAMA. 2021; 325(21):2204-2206. PMC: 8100911. DOI: 10.1001/jama.2021.7489. View

11.

Bert N, Tan A, Kunasegaran K, Tham C, Hafezi M, Chia A . SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020; 584(7821):457-462. DOI: 10.1038/s41586-020-2550-z. View

12.

Caillard S, Chavarot N, Francois H, Matignon M, Greze C, Kamar N . Is COVID-19 infection more severe in kidney transplant recipients?. Am J Transplant. 2020; 21(3):1295-1303. PMC: 7753418. DOI: 10.1111/ajt.16424. View

13.

Garcia-Basteiro A, Moncunill G, Tortajada M, Vidal M, Guinovart C, Jimenez A . Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. Nat Commun. 2020; 11(1):3500. PMC: 7343863. DOI: 10.1038/s41467-020-17318-x. View

14.

Schillie S, Spradling P, Murphy T . Immune response of hepatitis B vaccine among persons with diabetes: a systematic review of the literature. Diabetes Care. 2012; 35(12):2690-7. PMC: 3507602. DOI: 10.2337/dc12-0312. View

15.

Crepin T, Carron C, Roubiou C, Gaugler B, Gaiffe E, Simula-Faivre D . ATG-induced accelerated immune senescence: clinical implications in renal transplant recipients. Am J Transplant. 2015; 15(4):1028-38. DOI: 10.1111/ajt.13092. View

16.

Loinaz C, de Juanes J, Gonzalez E, Lopez A, Lumbreras C, Gomez R . Hepatitis B vaccination results in 140 liver transplant recipients. Hepatogastroenterology. 1997; 44(13):235-8. View

17.

Cordero E, Roca-Oporto C, Bulnes-Ramos A, Aydillo T, Gavalda J, Moreno A . Two Doses of Inactivated Influenza Vaccine Improve Immune Response in Solid Organ Transplant Recipients: Results of TRANSGRIPE 1-2, a Randomized Controlled Clinical Trial. Clin Infect Dis. 2017; 64(7):829-838. DOI: 10.1093/cid/ciw855. View

18.

Natori Y, Shiotsuka M, Slomovic J, Hoschler K, Ferreira V, Ashton P . A Double-Blind, Randomized Trial of High-Dose vs Standard-Dose Influenza Vaccine in Adult Solid-Organ Transplant Recipients. Clin Infect Dis. 2017; 66(11):1698-1704. DOI: 10.1093/cid/cix1082. View

19.

Meneghini M, Melilli E, Martorell J, Revuelta I, Rigol-Monzo E, Manonelles A . Combining Sensitive Crossmatch Assays With Donor/Recipient Human Leukocyte Antigen Eplet Matching Predicts Living-Donor Kidney Transplant Outcome. Kidney Int Rep. 2018; 3(4):926-938. PMC: 6035161. DOI: 10.1016/j.ekir.2018.03.015. View

20.

Walsh E, Frenck Jr R, Falsey A, Kitchin N, Absalon J, Gurtman A . Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med. 2020; 383(25):2439-2450. PMC: 7583697. DOI: 10.1056/NEJMoa2027906. View